The EVERY Company

The EVERY Company, formerly known as Clara Foods Co., is a biotechnology company headquartered in South San Francisco, California. It develops proteins and other functional ingredients that have traditionally been sourced from animals, with a particular focus on egg proteins. Its production platform uses yeast and microbial fermentation: microorganisms are supplied with sugar and programmed to produce proteins that are molecularly or functionally similar to proteins found in eggs and other animal-derived products. The company was founded in 2015 by Arturo Elizondo and Dave Anchel after the two met at a conference in 2014. Their initial concept was to create egg proteins without chickens, addressing the environmental, animal-welfare, and supply-chain limitations associated with conventional egg production. The founders joined the inaugural cohort of IndieBio, the biotechnology accelerator operated by SOSV, which helped support the early development of the company’s fermentation-based approach. EVERY’s central proposition is that food manufacturers should be able to obtain the functionality of animal-derived ingredients without raising and slaughtering animals. Egg white proteins are especially useful in commercial food production because they can foam, gel, bind, and provide structure. These characteristics make them important in products such as baked goods, confectionery, meringues, nutrition products, and certain industrial and pharmaceutical applications. By producing the relevant proteins through fermentation, EVERY seeks to offer ingredients that perform like conventional egg components while being suitable for animal-free formulations. The company received investment from Grupo Bimbo in 2019. In 2020, it released its first product, described as a digestive supplement. In April 2021, EVERY announced a partnership with ZX Ventures, the innovation arm of AB InBev. The arrangement was intended to support the scale-up of the company’s proprietary egg-protein production using fermentation, with production ambitions comparable to the scale of large brewing operations. The partnership was notable because it represented AB InBev’s first partnership with a food company. In 2022, EVERY introduced Every EggWhite, an animal-free egg-white replacement ingredient aimed at bakery customers. The ingredient was presented as suitable for applications including macarons, where egg-white functionality is important to texture and structure. The company has also developed an animal-free, bioidentical form of pepsin for industrial pharmaceutical use, potentially enabling vegan alternatives to medicines or manufacturing processes that rely on animal-derived pepsin. EVERY primarily operates as a business-to-business ingredient and biotechnology company rather than as a conventional consumer packaged-food brand. Its customers and commercial partners include food manufacturers, ingredient buyers, and other organizations seeking animal-free proteins with familiar functional performance. The company’s broader mission is to accelerate a transition toward more sustainable protein production and reduce dependence on factory farming. Its technology is part of the wider cellular-agriculture and precision-fermentation sectors, which use biological production systems to make food, nutrition, and industrial ingredients without obtaining them directly from livestock. In 2023, the company announced that actress Anne Hathaway had invested in EVERY. The investment was described as her first business-to-business investment and was associated with her stated view that the food system requires substantial change. The company remains a private biotechnology venture, and publicly available reference material does not establish a definitive current executive roster, ownership structure, revenue figure, or public-market listing.

The EVERY Company began as Clara Foods Co. and was founded in 2015 by Arturo Elizondo and Dave Anchel. The founders met at a conference in 2014 and subsequently developed the idea of producing egg proteins through microbial fermentation rather than obtaining them from chickens. Their work focused on using yeast to convert sugar into proteins with properties similar to those found in animal products. The company joined the inaugural cohort of SOSV’s IndieBio biotechnology accelerator, establishing an early connection to the emerging cellular-agriculture and synthetic-biology ecosystem. The original technical and commercial challenge was to reproduce the performance of egg proteins. Egg whites are not merely sources of nutrition; they also foam, gel, bind, and provide structure. Those properties are essential in baking, confectionery, nutrition products, and various industrial formulations. EVERY’s fermentation platform was designed to create animal-free proteins that could provide comparable functionality, allowing manufacturers to formulate products without conventional eggs. In 2019, Grupo Bimbo invested in the company. The investment connected EVERY with one of the world’s largest bakery companies and was relevant to the development of animal-free ingredients for large-scale food manufacturing. In 2020, the company released its first product, a digestive supplement, marking an early move from platform development toward commercialization. In April 2021, EVERY announced a partnership with ZX Ventures, the innovation arm of AB InBev. The collaboration was intended to help scale the production of EVERY’s proprietary egg protein through fermentation. The companies described an ambition to reach production volumes comparable to those associated with AB InBev’s brewing infrastructure. The relationship was significant because it was identified as AB InBev’s first partnership with a food company. EVERY continued expanding its ingredient portfolio. It developed what it described as an animal-free egg white for use in baking, nutrition, and industrial applications. In 2022, it launched Every EggWhite for bakery customers and demonstrated the ingredient in applications such as macarons. The company also developed an animal-free bioidentical pepsin for industrial pharmaceutical use, targeting applications in which conventionally sourced pepsin is derived from animals. The company’s strategy is primarily business-to-business. Rather than selling only finished consumer foods, EVERY aims to supply manufacturers with functional proteins and enzymes that can be incorporated into existing products and processes. This approach allows customers to preserve familiar product characteristics while addressing concerns about animal agriculture, resource use, and supply-chain resilience. In 2023, EVERY announced that actress Anne Hathaway had invested in the company. The announcement broadened the company’s public profile and reflected interest from outside the traditional biotechnology and food-industry investor base. Public reference material does not provide a complete current list of executives, detailed financial results, a confirmed website, or evidence that the company is publicly listed. The company is associated with the broader cellular-agriculture movement and remains focused on fermentation-derived alternatives to animal-sourced proteins.

• 2023

  Anne Hathaway investment

  [1]The EVERY Companyen.wikipedia.org

  The company announced an investment by actress Anne Hathaway.

• 2022

  Every EggWhite launch

  [1]The EVERY Companyen.wikipedia.org

  The company launched Every EggWhite, an animal-free egg-white replacement ingredient for bakery applications.

• 2021

  ZX Ventures partnership

  [1]The EVERY Companyen.wikipedia.org

  EVERY announced a partnership with ZX Ventures to support the scale-up of fermentation-derived egg protein.

• 2020

  First product release

  [1]The EVERY Companyen.wikipedia.org

  EVERY released a digestive supplement as its first reported product.

• 2019

  Grupo Bimbo investment

  [1]The EVERY Companyen.wikipedia.org

  Grupo Bimbo invested in the company, creating a connection with a major global bakery business.

• 2015

  Company founded

  [1]The EVERY Companyen.wikipedia.org

  The company was established as Clara Foods Co., later becoming The EVERY Company.

• 2015

  Joins IndieBio’s inaugural cohort

  [1]The EVERY Companyen.wikipedia.org

  The startup participated in the first cohort of SOSV’s IndieBio biotechnology accelerator.

• 2014

  Founders develop the initial concept

  [1]The EVERY Companyen.wikipedia.org

  Arturo Elizondo and Dave Anchel met at a conference and began developing an approach for producing egg proteins without chickens.

A business-to-business precision-fermentation company supplying animal-free proteins and functional ingredients designed to reproduce the performance of conventional animal-derived ingredients.

• Animal-free egg replacement ingredient · 2022

  Every EggWhite

  Every EggWhite is a fermentation-derived egg-white replacement ingredient introduced for bakery customers. It is intended to reproduce important functional characteristics of conventional egg white, including foaming, gelling, and binding. The ingredient can be used in applications such as macarons and other baked or confectionery products where egg white contributes to structure, texture, and aeration. It is positioned as an animal-free input for manufacturers rather than simply as a consumer-facing egg substitute.

• Food protein

  Animal-free egg white

  EVERY developed an animal-free egg white produced through microbial fermentation. The protein is designed for use in baking, nutrition, and industrial applications and is intended to provide functional behavior similar to conventional egg white. Its reported properties include the ability to foam, gel, and bind, enabling use in products such as meringue, scrambled-egg alternatives, and other formulations that depend on egg-white performance.

• Industrial and pharmaceutical enzyme

  Animal-free bioidentical pepsin

  The company has developed an animal-free, bioidentical form of pepsin for industrial pharmaceutical use. The product is intended to support vegan or animal-free alternatives in applications that traditionally use animal-derived pepsin. Public reference material identifies the industrial and pharmaceutical target markets but does not provide detailed commercial specifications or a launch date.

• Nutritional supplement · 2020

  Digestive supplement

  EVERY released a digestive supplement in 2020, representing its first reported product. Available reference material does not specify the product’s formulation, branding, distribution, or continuing commercial status.

• 2022

  Launch Every EggWhiteProduct launch

  Background

  Bakery manufacturers require egg-white functionality for aeration, binding, and structure, but conventional eggs carry animal-agriculture and supply-chain impacts.

  Action taken

  EVERY launched Every EggWhite as an animal-free egg replacement ingredient for bakery customers and presented applications including macarons.

  Aftermath

  The launch represented a move toward commercial ingredient sales and demonstrated the company’s business-to-business focus. Public reference material does not provide sales figures or customer volumes.

  Source

• 2021

  Partner with ZX Ventures to scale fermentation productionStrategy

  Background

  EVERY needed to expand production of its proprietary egg protein beyond laboratory and early commercial scale. ZX Ventures, the innovation arm of AB InBev, provided a connection to a company experienced in large-scale fermentation infrastructure.

  Action taken

  The companies announced a partnership intended to scale EVERY’s egg-protein production to volumes comparable to those associated with AB InBev’s breweries.

  Aftermath

  The partnership increased the strategic visibility of precision-fermented egg proteins and was described as AB InBev’s first partnership with a food company. Public reference material does not establish the partnership’s subsequent production volumes or commercial results.

  Source

1. 1The EVERY Companyen.wikipedia.org